Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In

Insmed Incorporated (NASDAQ:INSM) is one of the best strong buy healthcare stocks to invest in. Mizuho cut the price target on Insmed Incorporated (NASDAQ:INSM) to $204 from $211 on February 24, maintaining an Outperform rating on the shares. The rating update came after the fiscal Q4 report, with the firm stating that the company offered “highly positive comments” on the Brinsupri launch.

Insmed Incorporated (NASDAQ:INSM) reported its fiscal Q4 and full year 2025 results on February 19, reporting total company revenues of $606.4 million for the full year 2025 and BRINSUPRI total revenues of $144.6 million for fiscal Q4 and $172.7 for the full year 2025. ARIKAYCE total revenues came up to $119.2 million for the quarter and $433.8 million for the full year 2025, showing a 19% annual growth and surpassing the upper end of the full year 2025 guidance.

Insmed Incorporated (NASDAQ:INSM) expects full-year 2026 BRINSUPRI® revenues to be at least $1 billion, and reiterated its full-year 2026 ARIKAYCE® revenue guidance of $450 million to $470 million. The company ended fiscal year 2025 with around $1.4 billion of cash, cash equivalents, and marketable securities.

Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company that develops and commercializes therapies for patients with rare diseases. The company focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.